Download App

Log in to access Online Inquiry
Company Overview More
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company’s lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.
CEO: Countouriotis M.D., Athena Maria
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

TPTX Turning Point Therapeutics

36.740+1.380+3.90%
Close 05/20 20:00 ET
36.74000.00%
Post Mkt Price 05/20 16:00 ET
High
38.000
Open
36.250
Turnover
22.48M
Low
34.480
Pre Close
35.360
Volume
621.45K
Market Cap
1.82B
P/E(TTM)
Loss
52wk High
83.060
Shares
49.67M
P/E(Static)
Loss
52wk Low
23.770
Float Cap
1.62B
Bid/Ask %
-100.00%
Historical High
141.300
Shs Float
44.09M
Volume Ratio
1.00
Historical Low
23.770
Dividend TTM
--
Div Yield TTM
--
P/B
2.05
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.41%
Amplitude
9.96%
Avg Price
36.175
Lot Size
1
Float Cap
1.62B
Bid/Ask %
-100.00%
Historical High
141.300
Shs Float
44.09M
Volume Ratio
1.00
Historical Low
23.770
Dividend TTM
--
P/B
2.05
Dividend LFY
--
Turnover Ratio
1.41%
Amplitude
9.96%
Avg Price
36.175
Lot Size
1
Price Forecast

No Data

News

Comment